Tuesday, 25 May 2021 05:26

Qorvo Omnia™ SARS-CoV-2 Antigen Test

In April 2021, Qorvo were granted emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the Qorvo Omnia™ SARS-CoV-2 Antigen Test. The EUA approval is a major milestone in the collaboration between Qorvo and SCHOTT MINIFAB over the past two years.

Are you developing a diagnostic microfluidic product? Validating assay maturity is critical for commercial success.

The TearLab success story began in 2007 when SCHOTT MINIFAB was approached to help turn the early stage eye health concept into a commercial product.

The relationship between TearLab and SCHOTT MINIFAB came at a pivotal moment. Prior to this partnership TearLab had invested considerable time and money with another developer / manufacturer only to be told that the concept was unworkable. Many other microfluidics experts had also voiced the opinion that the product was a technical impossibility.